Paul M. Nurse
5 min
Paul Nurse’s Nobel Lecture details the discovery and characterization of the molecular mechanisms that control the eukaryotic cell cycle. The primary goal was to identify the genes and proteins responsible for ensuring that cells replicate their DNA and divide in the correct sequence, while coordinating these events with cell growth.
Using the fission yeast Schizosaccharomyces pombe as a model, Nurse employed genetic screening to isolate temperature-sensitive mutants that were unable to complete the cell cycle. By identifying genes like cdc2 and wee1, the team mapped a regulatory network that controls the onset of mitosis. They later used molecular cloning and biochemical assays to demonstrate that the cdc2 gene encodes a protein kinase, and that its activity is periodically regulated throughout the cell cycle by phosphorylation and association with cyclin subunits.
The research established that the Cdc2 protein kinase is a universal regulator of the cell cycle across eukaryotes. It functions as a master switch, required for both the G1/S and G2/M transitions. The study revealed that Cdc2 activity is inhibited by Wee1 (a kinase) and activated by Cdc25 (a phosphatase), creating a regulatory circuit that ensures mitosis only occurs after DNA replication is complete. Furthermore, the discovery that human CDC2 could rescue fission yeast mutants demonstrated that these control mechanisms have been conserved over more than a billion years of evolution.
Understanding these cell cycle controls is fundamental to biology, as they underpin growth, development, and heredity. Because cancer is characterized by defective control of cell growth and division, identifying the role of CDKs provided a critical foundation for modern cancer research and the development of targeted therapies that aim to restore or inhibit these regulatory pathways.
Alex: [building the point] Yes, and this is where the system's logic becomes particularly clear. CDK activity during G2 and M phase actively suppresses re-initiation of S-phase. If you delete the G2/M cyclin and let CDK activity drop prematurely, the cell immediately initiates a second round of DNA replication without completing division. So Cdc2 is doing two things simultaneously: driving the cell into mitosis and acting as a block against re-replication. It's a one-way valve for genome integrity.
Sam: [summarizing] So it's a dual-purpose regulator—accelerator and lock at the same time. That's an efficient design, but I imagine it's brittle if the timing drifts.
Alex: [measured] Which is exactly why the feedback architecture is so elaborate. The system has evolved to be robust against perturbation, and that robustness is precisely what makes it difficult to target therapeutically. [[RP_SECTION:downstream-substrate-identification|Downstream substrate identification]]
Sam: [reflective] And that brings us to what the paper is candid about as a significant gap. We've mapped the regulatory switch with real precision—the Wee1 and Cdc25 interplay, the bistable kinetics—but the downstream substrates, the proteins Cdc2 actually phosphorylates to execute the physical changes of mitosis, remain largely uncharacterized.
Alex: [measured, nodding] Nurse flags this directly, and it's a fair criticism of where the field stood. We know the switch; we don't fully know what the switch turns on. The actual machinery driving chromosome condensation, spindle assembly, nuclear envelope breakdown—the specific substrates mediating those events were, and to a significant extent still are, a black box.
Sam: [curious] So how strong is the causal claim that Cdc2 is the primary driver, if we can't fully account for the downstream mechanism?
Alex: [analytical, precise] The genetic rescue experiments carry most of the load there. If you replace the yeast kinase with the human version and the cycle runs normally, that's strong evidence the kinase is the functional heart of the system—not merely a signal in a parallel pathway. But it doesn't tell you which substrates matter most, and that gap has real consequences for intervention.
Sam: [following the logic] Because hitting the master switch is a blunt instrument. It affects every dividing cell. If you want to stop a cancer cell specifically, you'd need to know which downstream targets to hit. [[RP_SECTION:therapeutic-implications|Therapeutic implications]]
Alex: [measured, deliberate] That's the practical horizon. The field has been moving toward in vivo substrate identification—phosphoproteomics, proximity labeling, conditional kinase analogs that let you map what gets phosphorylated when Cdc2 is active in a specific context. Once that substrate map is filled in, you could in principle target the effectors rather than the switch itself. More selective, fewer off-target effects.
Sam: [settling] So the foundational picture Nurse laid out—a bistable switch, evolutionarily conserved, integrated with checkpoint logic—that part is solid. The open question is what the switch is actually doing at the molecular level downstream.
Alex: [concluding with quiet confidence] That's a fair summary of where the evidence lands. The regulatory logic is well-established; the mechanistic detail of execution is still being filled in. And closing that gap is what would move this from a beautiful circuit diagram to a genuinely actionable therapeutic target. Thanks for listening to ResearchPod.